Daratumumab in multiple myeloma von Nooka, Ajay K., Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Heffner, Thomas L., Gupta, Vikas A., Sullivan, Harold C., Neish, Andrew S., Dhodapkar, Madhav V., Lonial, Sagar

Volltext

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma von Joseph, Nisha S., Kaufman, Jonathan L., Dhodapkar, Madhav, Hofmeister, Craig C., Almaula, Dhwani K., Heffner, Leonard T., Gupta, Vikas A., Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K.

Volltext

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis von Barwick, Benjamin G., Neri, Paola, Bahlis, Nizar J., Nooka, Ajay K., Dhodapkar, Madhav V., Jaye, David L., Hofmeister, Craig C., Kaufman, Jonathan L., Gupta, Vikas A., Auclair, Daniel, Keats, Jonathan J., Lonial, Sagar, Vertino, Paula M., Boise, Lawrence H.

Volltext

How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma von Hofmeister, Craig C, Lonial, Sagar

Volltext

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody von Benson, Don M., Bakan, Courtney E., Mishra, Anjali, Hofmeister, Craig C., Efebera, Yvonne, Becknell, Brian, Baiocchi, Robert A., Zhang, Jianying, Yu, Jianhua, Smith, Megan K., Greenfield, Carli N., Porcu, Pierluigi, Devine, Steven M., Rotem-Yehudar, Rinat, Lozanski, Gerard, Byrd, John C., Caligiuri, Michael A.

Volltext

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC von Collins, Shauna M., Bakan, Courtney E., Swartzel, Gina D., Hofmeister, Craig C., Efebera, Yvonne A., Kwon, Hakju, Starling, Gary C., Ciarlariello, David, Bhaskar, Shakthi, Briercheck, Edward L., Hughes, Tiffany, Yu, Jianhua, Rice, Audie, Benson, Don M.

Volltext

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia von Chen, Christine, Siegel, David, Gutierrez, Martin, Jacoby, Meagan, Hofmeister, Craig C., Gabrail, Nashat, Baz, Rachid, Mau-Sorensen, Morten, Berdeja, Jesus G., Savona, Michael, Savoie, Lynn, Trudel, Suzanne, Areethamsirikul, Nuchanan, Unger, T.J., Rashal, Tami, Hanke, Tim, Kauffman, Michael, Shacham, Sharon, Reece, Donna

Volltext

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study von Richardson, Paul G., Siegel, David S., Vij, Ravi, Hofmeister, Craig C., Baz, Rachid, Jagannath, Sundar, Chen, Christine, Lonial, Sagar, Jakubowiak, Andrzej, Bahlis, Nizar, Song, Kevin, Belch, Andrew, Raje, Noopur, Shustik, Chaim, Lentzsch, Suzanne, Lacy, Martha, Mikhael, Joseph, Matous, Jeffrey, Vesole, David, Chen, Min, Zaki, Mohamed H., Jacques, Christian, Yu, Zhinuan, Anderson, Kenneth C.

Volltext

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma von Benson, Jr, Don M, Cohen, Adam D, Jagannath, Sundar, Munshi, Nikhil C, Spitzer, Gary, Hofmeister, Craig C, Efebera, Yvonne A, Andre, Pascale, Zerbib, Robert, Caligiuri, Michael A

Volltext

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant von Thomas, Melissa, Li, Junan, King, Kevan, Persaud, Avinash K, Duah, Ernest, Vangundy, Zachary, Hofmeister, Craig C, Lamba, Jatinder K, Tan, Aik Choon, Fridley, Brooke L, Poi, Ming J, Seligson, Nathan D

Volltext

Ninety-minute daratumumab infusion is safe in multiple myeloma von Barr, Hallie, Dempsey, Jessica, Waller, Allyson, Huang, Ying, Williams, Nita, Sharma, Nidhi, Benson, Don M., Rosko, Ashley E., Efebera, Yvonne A., Hofmeister, Craig C.

Volltext

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma von McCarthy, Philip L, Owzar, Kouros, Hofmeister, Craig C, Hurd, David D, Hassoun, Hani, Richardson, Paul G, Giralt, Sergio, Stadtmauer, Edward A, Weisdorf, Daniel J, Vij, Ravi, Moreb, Jan S, Callander, Natalie Scott, Van Besien, Koen, Gentile, Teresa, Isola, Luis, Maziarz, Richard T, Gabriel, Don A, Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H, Levitan, Denise, McClune, Brian, Schlossman, Robert, Hars, Vera, Postiglione, John, Jiang, Chen, Bennett, Elizabeth, Barry, Susan, Bressler, Linda, Kelly, Michael, Seiler, Michele, Rosenbaum, Cara, Hari, Parameswaran, Pasquini, Marcelo C, Horowitz, Mary M, Shea, Thomas C, Devine, Steven M, Anderson, Kenneth C, Linker, Charles

Volltext

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect von Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.

Volltext

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation von Pichiorri, Flavia, Palmieri, Dario, De Luca, Luciana, Consiglio, Jessica, You, Jia, Rocci, Alberto, Talabere, Tiffany, Piovan, Claudia, Lagana, Alessandro, Cascione, Luciano, Guan, Jingwen, Gasparini, Pierluigi, Balatti, Veronica, Nuovo, Gerard, Coppola, Vincenzo, Hofmeister, Craig C, Marcucci, Guido, Byrd, John C, Volinia, Stefano, Shapiro, Charles L, Freitas, Michael A, Croce, Carlo M

Volltext

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma von Benson, Don M., Hofmeister, Craig C., Padmanabhan, Swaminathan, Suvannasankha, Attaya, Jagannath, Sundar, Abonour, Rafat, Bakan, Courtney, Andre, Pascale, Efebera, Yvonne, Tiollier, Jérôme, Caligiuri, Michael A., Farag, Sherif S.

Volltext

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy von Robinson, M Hope, Villa, Nancy Y, Jaye, David L, Nooka, Ajay K, Duffy, Alyssa, McCachren, Samuel S, Manalo, Julia, Switchenko, Jeffrey M, Barnes, Sierra, Potdar, Sayalee, Azeem, Maryam I, Horvat, Ava A, Parihar, Vaunita C, Gong, Jingjing, Liang, Yan, Smith, Geoffrey H, Gupta, Vikas A, Boise, Lawrence H, Kaufman, Jonathan L, Hofmeister, Craig C, Joseph, Nisha S, Lonial, Sagar, Dhodapkar, Kavita M, Dhodapkar, Madhav V

Volltext

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression von Gupta, Vikas A., Barwick, Benjamin G., Matulis, Shannon M., Shirasaki, Ryosuke, Jaye, David L., Keats, Jonathan J., Oberlton, Benjamin, Joseph, Nisha S., Hofmeister, Craig C., Heffner, Leonard T., Dhodapkar, Madhav V., Nooka, Ajay K., Lonial, Sagar, Mitsiades, Constantine S., Kaufman, Jonathan L., Boise, Lawrence H.

Volltext

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) von Landgren, C. Ola, Chari, Ajai, Cohen, Yael C., Spencer, Andrew, Voorhees, Peter, Estell, Jane A., Sandhu, Irwindeep, Jenner, Matthew W., Williams, Catherine, Cavo, Michele, van de Donk, Niels W. C. J., Beksac, Meral, Moreau, Philippe, Goldschmidt, Hartmut, Kuppens, Steven, Bandekar, Rajesh, Clemens, Pamela L., Neff, Tobias, Heuck, Christoph, Qi, Ming, Hofmeister, Craig C.

Volltext

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting von Viola, Domenico, Dona, Ada, Caserta, Enrico, Troadec, Estelle, Besi, Francesca, McDonald, Tinisha, Ghoda, Lucy, Gunes, Emine Gulsen, Sanchez, James F., Khalife, Jihane, Martella, Marianna, Karanes, Chatchada, Htut, Myo, Wang, Xiuli, Rosenzweig, Michael, Chowdhury, Arnab, Sborov, Douglas, Miles, Rodney R., Yazaki, Paul J., Ebner, Todd, Hofmeister, Craig C., Forman, Stephen J., Rosen, Steven T., Marcucci, Guido, Shively, John, Keats, Jonathan J., Krishnan, Amrita, Pichiorri, Flavia

Volltext

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone von Schmidt, Timothy M., Barwick, Benjamin G., Joseph, Nisha, Heffner, Leonard T., Hofmeister, Craig C., Bernal, Leon, Dhodapkar, Madhav V., Gupta, Vikas A., Jaye, David L., Wu, Jiayi, Goyal, Subir, Chen, Zhengjia, Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K., Kaufman, Jonathan L.

Volltext